Article Text

Download PDFPDF
Absolute benefits of empagliflozin in type 2 diabetes: a game changer?

Statistics from Altmetric.com

Footnotes

  • Contributors CRK: Acquired relevant data, undertook its analysis and interpretation of findings; conceived the message for the editorial and produced the first draft; critically revised the manuscript and approved the final version; agrees to be accountable for the contents, including its integrity and accuracy.

    KCBT: Provided necessary reference material; critically revised the manuscript and approved the final version; agrees to be accountable for the contents, including its integrity and accuracy.

    BMYC: Contributed to the conception of the message; drafted sections of the manuscript and reviewed data interpretation; critically revised the manuscript and approved the final version; agrees to be accountable for the contents, including its integrity and accuracy.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.